Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma
the ONA take:
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for patients with aggressive renal cell carcinoma (RCC), a recent study published in the journal Cancer has shown.
Because no standard treatment exists for patients with sarcomatoid RCC, a type of kidney cancer associated with an aggressive biology and a poor prognosis, and treatment options for patients with poor-risk disease provide minimal benefit, researchers sought to evaluate the efficacy and safety of antiangiogenic therapy in combination with cytotoxic therapy in clinically aggressive RCC.
For the single-arm, phase 2 trial, researchers enrolled 39 patients with sarcomatoid RCC and 33 with poor-risk RCC. All patients received sunitinib plus gemcitabine.
Results showed that the objective response rate was 26% and 24% for patients with sarcomatoid RCC and poor-risk RCC, respectively.
The median time to progression was 5 months for patients with sarcomatoid RCC and 5.5 months for those with poor-risk RCC. Median overall survival was 10 months and 15 months, respectively.
In regard to safety, the most common grade 3 or higher treatment-associated adverse events were neutropenia, anemia, and fatigue.
“The combination may be more efficacious than either therapy alone and is currently under further investigation,” the authors conclude.
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|